Journal of hypertension
-
Journal of hypertension · Jul 2010
Meta Analysis Comparative StudyInfluence of blood pressure reduction on composite cardiovascular endpoints in clinical trials.
The use of a composite cardiovascular endpoint (CCEP) is frequent in clinical trials. However, the relation between the reduction in blood pressure (BP) and the risk of CCEP is poorly known. ⋯ BP reduction is important to reduce the risk of CCEP in clinical trials. A significant difference between two treatment groups in the risk of CCEP may be anticipated for a SBP/DBP reduction differing by 4.6/2.2 mmHg or more.